4-Methyl-N-propyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide, 98%, 1g

1-(2-chloroethyl)-5-methyl-1H-pyrazole-4-carbaldehyde, 95.0%, 25g

Thalidomide-O-amido-PEG3-C2-NH2 (TFA), 500mg

Methyl 2-amino-3-hydroxybenzoate, 95.0%, 250mg

4,4,4-Trifluoro-3-oxo-2-(triphenylphosphoranyliden)-butyric acid ethyl ester, 5g

2-(4-Bromo-benzoylamino)-6-methyl-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid, 250mg

Di-n-alkyldimethylammonium Chloride (mixture)>95.0%(T)25g

1-Pyridin-4-ylpiperidin-4-one, 95.0%, 250mg

2,2-Dimethyl-4-oxo-3,8,11,14,17,20-hexaoxa-5-azatricosan-23-oic acid, 97%, 250mg

2-{1-[(tert-butoxy)carbonyl]piperidin-4-yl}-2-{[(9h-fluoren-9-ylmethoxy)carbonyl]amino}acetic acid, 98+%, 100mg

(S)-(+)-6,6'-Dibromo-1,1'-bi-2-naphthol>98.0%(HPLC)5g

3-(Methylsulfonyl)pyrrolidine, 95.0%, 1g

Solution étalon multi-éléments ICP CR-29, ROTI®Star, 250 ml, HDPE